Welcome to Paid Research Studies


Browse Locations ... United States» ... North Dakota» ... Bismarck






  • Condition:   Breast Cancer
    Interventions:   Drug: RTA 408 Lotion 0.5%;   Drug: RTA 408 Lotion 3%;   Drug: Lotion vehicle/Placebo
    Sponsor:   Reata Pharmaceuticals, Inc.AbbVieReata Pharmaceuticals, Inc.
    Recruiting - verified August 2014

  • Conditions:   Mucositis;   Oral Complications;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Basal Cell Carcinoma of the Lip;   Recurrent Lymphoepithelioma of the Nasopharynx;   Recurrent Lymphoepithelioma of the Oropharynx;   Recurrent Mucoepidermoid Carcinoma of the Oral Cavity;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Stage I Adenoid Cystic Carcinoma of the Oral Cavity;   Stage I Basal Cell Carcinoma of the Lip;   Stage I Lymphoepithelioma of the Nasopharynx;   Stage I Lymphoepithelioma of the Oropharynx;   Stage I Mucoepidermoid Carcinoma of the Oral Cavity;   Stage I Salivary Gland Cancer;   Stage I Squamous Cell Carcinoma of the Larynx;   Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage I Squamous Cell Carcinoma of the Nasopharynx;   Stage I Squamous Cell Carcinoma of the Oropharynx;   Stage I Verrucous Carcinoma of the Larynx;   Stage I Verrucous Carcinoma of the Oral Cavity;   Stage II Adenoid Cystic Carcinoma of the Oral Cavity;   Stage II Basal Cell Carcinoma of the Lip;   Stage II Lymphoepithelioma of the Nasopharynx;   Stage II Lymphoepithelioma of the Oropharynx;   Stage II Mucoepidermoid Carcinoma of the Oral Cavity;   Stage II Salivary Gland Cancer;   Stage II Squamous Cell Carcinoma of the Larynx;   Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage II Squamous Cell Carcinoma of the Nasopharynx;   Stage II Squamous Cell Carcinoma of the Oropharynx;   Stage II Verrucous Carcinoma of the Larynx;   Stage II Verrucous Carcinoma of the Oral Cavity;   Stage III Adenoid Cystic Carcinoma of the Oral Cavity;   Stage III Basal Cell Carcinoma of the Lip;   Stage III Lymphoepithelioma of the Nasopharynx;   Stage III Lymphoepithelioma of the Oropharynx;   Stage III Mucoepidermoid Carcinoma of the Oral Cavity;   Stage III Salivary Gland Cancer;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage III Squamous Cell Carcinoma of the Nasopharynx;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Verrucous Carcinoma of the Larynx;   Stage III Verrucous Carcinoma of the Oral Cavity;   Stage IV Lymphoepithelioma of the Nasopharynx;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IVA Basal Cell Carcinoma of the Lip;   Stage IVA Lymphoepithelioma of the Oropharynx;   Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IVA Salivary Gland Cancer;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IVB Basal Cell Carcinoma of the Lip;   Stage IVB Lymphoepithelioma of the Oropharynx;   Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IVB Salivary Gland Cancer;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IVC Basal Cell Carcinoma of the Lip;   Stage IVC Lymphoepithelioma of the Oropharynx;   Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IVC Salivary Gland Cancer;   Stage IVC Squamous Cell Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Verrucous Carcinoma of the Larynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity;   Tongue Cancer
    Interventions:   Drug: acetylcysteine;   Other: placebo;   Other: quality-of-life assessment;   Other: questionnaire administration
    Sponsor:   Mayo ClinicNational Cancer Institute (NCI)Mayo Clinic
    Recruiting - verified September 2014

  • Conditions:   Implantable Cardioverter Defibrillators;   CRT-D Cardiac Resynchronization Therapy Defibrillator
    Intervention:  
    Sponsor:   Boston Scientific CorporationBoston Scientific Corporation
    Recruiting - verified August 2014

  • Conditions:   Anemia;   Fever, Sweats, and Hot Flashes;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Small Lymphocytic Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma;   Weight Changes
    Interventions:   Drug: ibrutinib;   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Biological: rituximab;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Conditions:   Estrogen Receptor-positive Breast Cancer;   HER2-positive Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Drug: docetaxel;   Drug: carboplatin;   Biological: trastuzumab;   Biological: pertuzumab;   Drug: goserelin acetate;   Procedure: therapeutic conventional surgery;   Radiation: whole breast irradiation;   Other: laboratory biomarker analysis;   Drug: aromatase inhibition therapy;   Other: quality-of-life assessment
    Sponsor:   National Cancer Institute (NCI)National Cancer Institute (NCI)
    Recruiting - verified April 2014

  • Condition:   Lymphoma
    Interventions:   Drug: Bendamustine;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone;   Drug: PCI-32765 (Ibrutinib);   Drug: Placebo
    Sponsor:   Janssen Research & Development, LLCPharmacyclicsJanssen Research & Development, LLC
    Recruiting - verified August 2014

  • Conditions:   Recurrent Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
    Interventions:   Biological: bevacizumab;   Biological: ipilimumab;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Condition:   Multiple Sclerosis
    Intervention:   Drug: TERIFLUNOMIDE HMR1726
    Sponsor:   SanofiSanofi
    Recruiting - verified September 2014

  • Conditions:   Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
    Interventions:   Drug: ibrutinib;   Biological: rituximab;   Drug: bendamustine hydrochloride;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
    Sponsor:   National Cancer Institute (NCI)National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Conditions:   Stage IB Breast Cancer;   Stage II Breast Cancer
    Interventions:   Radiation: regional nodal XRT;   Radiation: chestwall XRT;   Radiation: WBI
    Sponsors:   NSABP Foundation IncNational Cancer Institute (NCI);   Radiation Therapy Oncology GroupNSABP Foundation Inc
    Recruiting - verified September 2014

  • Conditions:   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma
    Interventions:   Drug: lenalidomide;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: vincristine sulfate;   Drug: prednisone;   Other: laboratory biomarker analysis;   Procedure: positron emission tomography
    Sponsor:   National Cancer Institute (NCI)National Cancer Institute (NCI)
    Recruiting - verified May 2014

  • Condition:   Rheumatoid Arthritis
    Interventions:   Drug: methotrexate;   Drug: placebo;   Drug: tocilizumab [RoActemra/Actemra]
    Sponsor:   Hoffmann-La RocheHoffmann-La Roche
    Recruiting - verified August 2014

  • Conditions:   Clear Cell Renal Cell Carcinoma;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
    Interventions:   Drug: cabozantinib-s-malate;   Drug: sunitinib malate;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)National Cancer Institute (NCI)
    Recruiting - verified May 2014

  • Conditions:   Extensive Stage Small Cell Lung Cancer;   Large Cell Lung Cancer;   Metastatic Carcinoma of Unknown Primary;   Neuroendocrine Carcinoma;   Newly Diagnosed Carcinoma of Unknown Primary;   Stage IV Non-small Cell Lung Cancer
    Interventions:   Drug: veliparib;   Other: placebo;   Drug: etoposide;   Drug: cisplatin;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Other: quality-of-life assessment
    Sponsor:   National Cancer Institute (NCI)National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Condition:   Non Small Cell Lung Cancer (NSCLC)
    Interventions:   Drug: Dacomitinib Plus Blinded Doxycycline or Placebo;   Drug: Dacomitinib Plus Probiotic Plus Topical Alclometasone cream;   Drug: Dacomitinib
    Sponsor:   PfizerPfizer
    Recruiting - verified September 2014

  • Conditions:   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-positive Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Drug: doxorubicin hydrochloride;   Drug: docetaxel;   Drug: cyclophosphamide;   Biological: trastuzumab;   Drug: paclitaxel;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)National Cancer Institute (NCI)
    Recruiting - verified July 2014

  • Conditions:   Recurrent Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
    Interventions:   Biological: ipilimumab;   Biological: recombinant interferon alfa-2b;   Other: quality-of-life assessment
    Sponsor:   National Cancer Institute (NCI)National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Conditions:   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Drug: systemic chemotherapy;   Drug: tamoxifen citrate;   Drug: anastrozole;   Drug: exemestane;   Drug: letrozole;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
    Sponsor:   National Cancer Institute (NCI)National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Condition:   Influenza, Human
    Interventions:   Drug: 300mg intravenous (IV) zanamivir and oral oseltamivir placebo;   Drug: 600mg intravenous (IV) zanamivir and oral oseltamivir placebo;   Drug: 75mg oral oseltamivir and intravenous zanamivir placebo
    Sponsor:   GlaxoSmithKlineGlaxoSmithKline
    Recruiting - verified August 2014

  • Condition:   Lymphoma, Follicular
    Interventions:   Biological: Ofatumumab;   Biological: Rituximab
    Sponsor:   GlaxoSmithKlineGlaxoSmithKline
    Recruiting - verified August 2014

  • Conditions:   Light Chain Deposition Disease;   Smoldering Multiple Myeloma
    Interventions:   Drug: lenalidomide;   Other: clinical observation;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
    Sponsor:   National Cancer Institute (NCI)National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Conditions:   Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer
    Interventions:   Drug: doxorubicin hydrochloride;   Drug: sorafenib tosylate;   Other: laboratory biomarker analysis;   Other: pharmacological study
    Sponsor:   National Cancer Institute (NCI)National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Conditions:   Distal Urethral Cancer;   Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter;   Proximal Urethral Cancer;   Recurrent Bladder Cancer;   Recurrent Prostate Cancer;   Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter;   Recurrent Urethral Cancer;   Regional Transitional Cell Cancer of the Renal Pelvis and Ureter;   Stage IV Bladder Cancer;   Stage IV Prostate Cancer;   Stage IV Urethral Cancer;   Transitional Cell Carcinoma of the Bladder;   Ureter Cancer;   Urethral Cancer Associated With Invasive Bladder Cancer
    Interventions:   Drug: gemcitabine hydrochloride;   Drug: cisplatin;   Other: placebo;   Biological: bevacizumab;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Conditions:   Anemia;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes
    Interventions:   Drug: lenalidomide;   Biological: epoetin alfa;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Condition:   Ductal Breast Carcinoma in Situ
    Interventions:   Biological: trastuzumab;   Radiation: whole breast irradiation;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Conditions:   Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Salivary Gland Squamous Cell Carcinoma;   Stage IV Salivary Gland Cancer;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IVA Salivary Gland Cancer;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Salivary Gland Cancer;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Salivary Gland Cancer;   Stage IVC Squamous Cell Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Verrucous Carcinoma of the Larynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity;   Tongue Cancer;   Untreated Metastatic Squamous Neck Cancer With Occult Primary
    Interventions:   Drug: docetaxel;   Drug: cisplatin;   Drug: carboplatin;   Drug: fluorouracil;   Biological: bevacizumab;   Other: laboratory biomarker analysis;   Other: cytology specimen collection procedure
    Sponsor:   National Cancer Institute (NCI)National Cancer Institute (NCI)
    Recruiting - verified August 2014

  • Conditions:   Brenner Tumor;   Fallopian Tube Cancer;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Primary Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer
    Interventions:   Drug: paclitaxel;   Drug: docetaxel;   Drug: carboplatin;   Biological: bevacizumab;   Drug: gemcitabine hydrochloride;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
    Sponsor:   National Cancer Institute (NCI)National Cancer Institute (NCI)
    Recruiting - verified August 2014